← Back to Search

Immunomodulator

RSLV-132 for Long COVID Syndrome

Phase 2
Waitlist Available
Research Sponsored by Resolve Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline to day 71

Summary

This trial is testing a drug called RSLV-132 to see if it can help reduce severe tiredness in people with long COVID syndrome. The study involves people who still feel very tired after recovering from COVID-19. The drug might work by helping the body handle the long-term effects of the virus.

Eligible Conditions
  • Long COVID Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline to day 71
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline to day 71 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
PROMIS Fatigue SF 7a T-score
Secondary study objectives
Digit Symbol Substitution Test
FACIT Fatigue questionnaire
Long COVID-19-related Symptom Assessment patient questionnaire
+2 more

Side effects data

From 2019 Phase 2 trial • 28 Patients • NCT03247686
30%
Fatigue
25%
Arthralgia
25%
Upper respiratory tract infection
20%
Viral upper respiratory tract infection
15%
Conjunctivitis
15%
Headache
10%
Weight increased
10%
Rash papular
10%
Oropharyngeal pain
10%
Dermatitis contact
10%
Dizziness
10%
Rash
10%
Muscle spasms
10%
Urinary tract infection
10%
Constipation
10%
Cough
5%
Joint injury
5%
Pain in extremity
5%
Nausea
5%
Joint swelling
5%
Lower respiratory tract infection
5%
Osteoarthritis
5%
Infusion related reaction
5%
Oedema peripheral
5%
Hordeolum
5%
Parotitis
5%
Palpitations
5%
Diarrhoea
5%
Mouth ulceration
5%
Viral infection
5%
Sleep disorder
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
RSLV-132

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: RSLV-132Experimental Treatment1 Intervention
RSLV-132 is an enzymatically active ribonuclease designed to digest the ribonucleic acid contained in autoantibodies and immune complexes and thereby render them biologically inert. A dose of 10 mg/kg will be administered by intravenous infusion on Days: 1, 8, 15, 29, 43, and 57
Group II: PlaceboPlacebo Group1 Intervention
Sodium chloride 0.9% will be administered by intravenous infusion on Days: 1, 8, 15, 29, 43, and 57
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
RSLV-132
2021
Completed Phase 2
~240

Find a Location

Who is running the clinical trial?

Resolve TherapeuticsLead Sponsor
4 Previous Clinical Trials
230 Total Patients Enrolled
James PosadaStudy DirectorResolve Therapeutics LLC
1 Previous Clinical Trials
106 Total Patients Enrolled
~26 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top